Theratechnologies (NASDAQ:THTX) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Theratechnologies (NASDAQ:THTX) released its earnings results on Tuesday. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.03), Fidelity Earnings reports. Theratechnologies had a negative net margin of 37.10% and a negative return on equity of 112.84%. During the same quarter last year, the business posted ($0.09) earnings per share.

NASDAQ:THTX opened at $3.57 on Thursday. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.41 and a quick ratio of 1.74. The firm has a 50-day moving average of $3.61 and a 200-day moving average of $3.63. The company has a market cap of $338.13 million, a PE ratio of -11.90 and a beta of 1.65. Theratechnologies has a one year low of $1.83 and a one year high of $4.46.

A hedge fund recently raised its stake in Theratechnologies stock. Morgan Stanley lifted its holdings in shares of Theratechnologies Inc. (NASDAQ:THTX) by 143.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,716,512 shares of the company’s stock after acquiring an additional 1,012,777 shares during the period. Morgan Stanley owned approximately 1.81% of Theratechnologies worth $6,660,000 at the end of the most recent reporting period. Institutional investors own 19.29% of the company’s stock.

Several equities analysts have recently weighed in on the stock. Zacks Investment Research upgraded shares of Theratechnologies from a “sell” rating to a “hold” rating in a report on Wednesday, September 15th. Canaccord Genuity lowered shares of Theratechnologies from a “buy” rating to a “hold” rating and dropped their price objective for the company from $8.00 to $3.00 in a report on Thursday, July 29th. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to, the company has an average rating of “Hold” and an average price target of $3.17.

About Theratechnologies

Theratechnologies, Inc is a pharmaceutical company. It engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). The firm offers its product under the brand name of EGRIFTA, which approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.

Featured Article: Debt-To-Equity Ratio

Earnings History for Theratechnologies (NASDAQ:THTX)

Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with's FREE daily email newsletter.